Recently, the PI3K inhibitor alpelisib was approved by both the FDA and EMA for patients with PIK3CA-mutated, steroid hormone receptor (SHR)-positive and HER2-negative tumours [5]. The gene discussed is PIK3CA; the disease is neoplasm.